We found that T2DM individuals who were being treated with glibenclamide had significantly lower TNF-α and IL-8 but increased IL-6 when compared to monocytes from healthy control groups in response to Mtb infection (Figure 3A). The gene discussed is TNF; the disease is type 2 diabetes mellitus.